# A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

> **NCT00158093** · PHASE1 · COMPLETED · sponsor: **Mylan Bertek Pharmaceuticals** · enrollment: 260 (—)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Nebivolol
- **DRUG:** Atenolol
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT00158093
- **Lead sponsor:** Mylan Bertek Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2003-07
- **Target enrollment:** 260 (—)
- **Last updated:** 2005-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00158093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00158093, "A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00158093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*